Kane Biotech enrolls 28 participants for revyve studies

Executive Summary

• Kane Biotech Inc. has completed enrollment in its U.S. case series studies for its revyve anti-microbial wound gel and spray, exceeding the initial target of 25 participants by enrolling 28 total participants.
• The studies involved wound care and burn specialists in the United States, focusing on the company's FDA 510(k) cleared products designed to disrupt biofilms and treat challenging wounds and burns.
• Clinical data from these studies are anticipated to be presented at various medical meetings in 2025 and 2026.

Key Details

• Enrollment Status: Completed enrollment in U.S. case series studies for revyve anti-microbial wound gel and spray.
• Participant Count: 28 participants enrolled, exceeding the pre-defined target of 25 participants.
• Study Scope: Engaged wound care and burn specialists in the United States.
• Product Status: revyve anti-microbial wound gel and spray are U.S. FDA 510(k) cleared.
• Mechanism of Action: Products address biofilms and wound bacteria to disrupt biofilms and transform healing outcomes.
• Timeline: Data presentation anticipated at medical meetings in 2025 and 2026.

Notable Quotes

• "Interest from clinicians and patients in the U.S. case series is encouraging," said Dr. Robert Huizinga, interim chief executive officer. "revyve products can meaningfully improve outcomes for those suffering from challenging wounds and burns."